Sage Therapeutics
Stock Forecast, Prediction & Price Target

Sage Therapeutics (SAGE) stock Price Target by analysts

Last Year
Average Price Target

$13.6

Potential upside: 56.50%

Based on 5 analysts

Sage Therapeutics price prediction

Strike.market

What is Sage Therapeutics stock analysts` prediction?

Sage Therapeutics stock forecast: Based on 5 Wall Street analysts` predicted price targets for Sage Therapeutics in the last 3 months, the avarage price target is $13.6, with a high forecast of $NaN. The average price target represents a 56.50% change from the last price of $8.69.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Sage Therapeutics stock Price Target by analysts

Full breakdown of analysts given Sage Therapeutics price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Brian Abrahams
RBC Capital
33.33%
1/3
10 months ago $4 -53.97% downside $4.91 StreetInsider
Previous targets (2)
Yasmeen Rahimi
Piper Sandler
0%
0/2
10 months ago $26 199.19% upside $7.9 StreetInsider
Previous targets (1)
George Farmer
Scotiabank
0%
0/2
10 months ago $14 61.10% upside $8.48 TheFly
Previous targets (1)
Vamil Divan
Mizuho Securities
0%
0/2
10 months ago $10 15.07% upside $7.86 StreetInsider
Previous targets (1)
Douglas Tsao
H.C. Wainwright
0%
0/1
10 months ago $14 61.10% upside $8.48 TheFly
Previous targets (0)
Joon Lee
Truist Financial
0%
0/3
about 1 year ago $13 49.59% upside $7.95 TheFly
Previous targets (2)
Sumant Kulkarni
Canaccord Genuity
0%
0/1
about 1 year ago $9 3.56% upside $8.88 TheFly
Previous targets (0)
Joel Beatty
Robert W. Baird
0%
0/1
over 1 year ago $15 72.61% upside $11.93 TheFly
Previous targets (0)
Joon Lee
Truist Financial
0%
0/3
over 1 year ago $18 107.13% upside $13.58 StreetInsider
Previous targets (2)
George Farmer
Scotiabank
0%
0/2
over 1 year ago $19 118.64% upside $12.57 StreetInsider
Previous targets (1)
Brian Abrahams
RBC Capital
33.33%
1/3
over 1 year ago $26 199.19% upside $12.12 StreetInsider
Previous targets (2)
Salveen Richter
Goldman Sachs
0%
0/1
over 1 year ago $28 222.20% upside $12.11 StreetInsider
Previous targets (0)
Jay Olson
Oppenheimer
0%
0/2
over 1 year ago $17 95.62% upside $12.57 StreetInsider
Previous targets (1)
Vamil Divan
Mizuho Securities
0%
0/2
over 1 year ago $20 130.14% upside $12.11 StreetInsider
Previous targets (1)
Joon Lee
Truist Financial
0%
0/3
over 1 year ago $22 153.16% upside $12.32 StreetInsider
Previous targets (2)
Unknown
J.P. Morgan
N/A
almost 3 years ago $60 590.44% upside $40.99 Benzinga
N/A
Unknown
Guggenheim
N/A
almost 3 years ago $48 452.35% upside $35.27 Benzinga
N/A
Yasmeen Rahimi
Piper Sandler
0%
0/2
about 3 years ago $100 1050.74% upside $33.86 Pulse 2.0
Previous targets (1)
Gary Nachman
BMO Capital
100%
1/1
over 3 years ago $48 452.35% upside $36.65 StreetInsider
Previous targets (0)
Marc Goodman
Leerink Partners
100%
1/1
over 3 years ago $50 475.37% upside $34.71 TipRanks Contributor
Previous targets (0)
Brian Abrahams
RBC Capital
33.33%
1/3
over 3 years ago $37 325.77% upside $34.71 TipRanks Contributor
Previous targets (2)
Paul Matteis
Stifel Nicolaus
0%
0/1
over 3 years ago $58 567.43% upside $34.71 StreetInsider
Previous targets (0)
Jay Olson
Oppenheimer
0%
0/2
over 3 years ago $74 751.55% upside $33.58 StreetInsider
Previous targets (1)
Yatin Suneja
Guggenheim
100%
1/1
almost 4 years ago $55 532.91% upside $43.57 TheFly
Previous targets (0)
Akash Tewari
Jefferies
100%
1/1
almost 4 years ago $50 475.37% upside $45.64 TheFly
Previous targets (0)
Laura Chico
Wedbush
0%
0/1
about 4 years ago $80 820.59% upside $41.76 StreetInsider
Previous targets (0)
Neena Bitritto-Garg
Citigroup
0%
0/1
about 4 years ago $68 682.50% upside $54.88 TheFly
Previous targets (0)
Ritu Baral
Cowen & Co.
0%
0/1
about 4 years ago $105 1108.28% upside $58.8 StreetInsider
Previous targets (0)

Sage Therapeutics Financial Estimates

Sage Therapeutics Revenue Estimates

Sage Therapeutics EBITDA Estimates

Sage Therapeutics Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$6.30M
 
N/A
$7.68M
 
21.84%
$86.45M
 
1024.83%
Avg: $125.24M
Low: $41.78M
High: $466.34M
avg. 44.86%
Avg: $275.46M
Low: $124.82M
High: $950.06M
avg. 119.94%
Avg: $428.55M
Low: $194.19M
High: $1.47B
avg. 55.57%
Avg: $660.99M
Low: $299.52M
High: $2.27B
avg. 54.23%
Net Income
 
% change YoY
$-450.82M
 
N/A
$-503.26M
 
-11.63%
$-541.48M
 
-7.59%
Avg: $-325.83M
Low: $-450.56M
High: $214.81M
avg. 39.82%
Avg: $-201.29M
Low: $-433.21M
High: $722.82M
avg. 38.22%
Avg: $-69.21M
Low: $-289.55M
High: $-20.00M
avg. 65.61%
Avg: $59.33M
Low: $17.15M
High: $248.24M
avg. 185.73%
EBITDA
 
% change YoY
$-460.90M
 
N/A
$-546.98M
 
-18.67%
$-545.07M
 
0.35%
Avg: $-85.54M
Low: $-318.52M
High: $-28.54M
avg. 84.30%
Avg: $-188.14M
Low: $-648.91M
High: $-85.25M
avg. -119.94%
Avg: $-292.70M
Low: $-1.00B
High: $-132.64M
avg. -55.57%
Avg: $-451.47M
Low: $-1.55B
High: $-204.58M
avg. -54.23%
EPS
 
% change YoY
-$7.68
 
N/A
-$8.49
 
-10.54%
-$9.05
 
-6.59%
Avg: -$5.14
Low: -$7.53
High: $3.59
avg. 43.25%
Avg: -$2.93
Low: -$7.24
High: $12.08
avg. 42.87%
Avg: -$1.16
Low: -$4.84
High: -$0.33
avg. 60.57%
Avg: $0.99
Low: $0.29
High: $4.15
avg. 185.73%
Operating Expenses
 
% change YoY
$466.66M
 
N/A
$553.86M
 
18.68%
$664.14M
 
19.91%
Avg: $2.81B
Low: $939.49M
High: $10.48B
avg. 323.97%
Avg: $6.19B
Low: $2.80B
High: $21.36B
avg. 119.94%
Avg: $9.63B
Low: $4.36B
High: $33.23B
avg. 55.57%
Avg: $14.86B
Low: $6.73B
High: $51.25B
avg. 54.23%

FAQ

What is Sage Therapeutics stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 82.35% in 2025-2028.

We have gathered data from 17 analysts. Their low estimate is -450.56M, average is -325.83M and high is 214.81M.

What is Sage Therapeutics stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 68.65% in 2025-2028.

We have gathered data from 16 analysts. Their low revenue estimate is $41.78M, average is $125.24M and high is $466.34M.

What is Sage Therapeutics stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 83.10% in 2025-2028.

We have gathered data from 17 analysts. Their low earnings per share estimate is -$7.53, average is -$5.14 and high is $3.59.

What is the best performing analyst?

In the last twelve months 5 analysts have been covering Sage Therapeutics stock. The most successful analyst is Brian Abrahams whose win rate is 33.33%. He has correctly predicted 1/3 price targets.